NLRP3 inflammasome acts as a central neuroimmune convergence node in Parkinson's Disease pathogenesis

Historically, Parkinson's Disease (PD) was viewed primarily as a disorder of isolated dopaminergic degeneration. However, a growing understanding points to disrupted neuroimmune integration as a core pathological driver. The NLRP3 inflammasome has emerged as a critical, stress-responsive signaling platform within the degenerating nigrostriatal system. Current therapies for PD primarily manage symptoms, failing to halt or reverse disease progression. Understanding the precise regulatory mechanisms of NLRP3 offers a crucial avenue for developing disease-modifying interventions by targeting its upstream control points.

This comprehensive review synthesizes current evidence regarding the NLRP3 inflammasome's multifaceted role in Parkinson's Disease neuroinflammation. Researchers analyzed published studies to map how NLRP3 competence is dynamically regulated by interconnected upstream mechanisms. The review specifically focused on how priming set points, activation licensing, proteostatic persistence, and endogenous resolution are governed. It also evaluates emerging clinical efforts targeting NLRP3, highlighting translational challenges such as achieving sustained central target engagement, optimizing therapeutic timing, and validating CNS-relevant biomarkers.

The review establishes the NLRP3 inflammasome not as an isolated inflammatory switch, but as a dynamic convergence node deeply embedded within interconnected neuroimmune regulatory networks in Parkinson's Disease. Inflammasome competence, encompassing priming set points, activation licensing, proteostatic persistence, and endogenous resolution, is tightly governed by multiple upstream mechanisms. These include dopaminergic signalling, PINK1-Parkin-mediated mitophagy, autophagy-lysosomal clearance, redox regulators like Nrf2, nucleocytoplasmic transport pathways, and lipid signalling. Dysregulation across these axes stabilizes chronic neuroinflammatory amplification, significantly reducing the resilience of vulnerable neuronal circuits. This systems-level architecture links mitochondrial dysfunction and proteostatic failure directly to innate immune persistence, providing a comprehensive framework for understanding PD pathogenesis.

Crucially, the review clarifies how these interconnected pathways collectively dictate NLRP3 responsiveness, activation thresholds, and resolution capacity, moving beyond canonical views of inflammasome regulation. The authors further highlight the translational challenges in targeting NLRP3 clinically, emphasizing the need for sustained central target engagement and appropriate therapeutic timing.